| Trial ID: | L0258 |
| Source ID: | NCT00501592
|
| Associated Drug: |
INT-747
|
| Title: |
Study of INT-747 in Patients With Diabetes and Presumed NAFLD
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT00501592/results
|
| Conditions: |
Diabetes Mellitus, Type II|Fatty Liver
|
| Interventions: |
Drug: INT-747|Drug: Placebo
|
| Outcome Measures: |
Insulin Resistance and Glucose Homeostasis|Hepatocellular Function
|
| Sponsor/Collaborators: |
Intercept Pharmaceuticals
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
64
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
July 2007
|
| Completion Date: |
April 2009
|
| Results First Posted: |
January 27, 2012
|
| Last Update Posted: |
April 20, 2012
|
| Locations: |
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|UC San Diego VAMC, San Diego, California, United States|Diabetes & Glandular Disease Research Associates, Inc., San Antonio, Texas, United States|Virginia Commonwelath University, Richmond, Virginia, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT00501592
|
